Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 9:10:570103.
doi: 10.3389/fonc.2020.570103. eCollection 2020.

Incidence, Prognostic Factors and Survival for Hemangioblastoma of the Central Nervous System: Analysis Based on the Surveillance, Epidemiology, and End Results Database

Xiangdong Yin  1 , Hongzhou Duan  1 , Zhiqiang Yi  1 , Chunwei Li  1 , Runchun Lu  1 , Liang Li  1
Affiliations

Incidence, Prognostic Factors and Survival for Hemangioblastoma of the Central Nervous System: Analysis Based on the Surveillance, Epidemiology, and End Results Database

Xiangdong Yin et al. Front Oncol. .

Abstract

Background: Hemangioblastomas are uncommon, benign neoplasms of the central nervous system (CNS). This study aims to evaluate the incidence, demographics, clinical characteristics, and prognosis of CNS hemangioblastomas using the data from the Surveillance, Epidemiology, and End Results (SEER) Program.

Methods: Univariate and multivariate analyses using the Cox proportional hazards model were employed to identify prognostic factors of overall survival. The Kaplan-Meier method was utilized to evaluate overall survival distribution by treatment modality. A nomogram was further built to predict survival at 3 and 5 years.

Results: The overall incidence rate of CNS hemangioblastomas was 0.141 per 100,000 person-years. Through univariate analysis and multivariate analyses, age between 60 and 79 years (HR = 3.697, p < 0.001), age greater than 80 years (HR = 12.318, p < 0.001), African American race (HR = 1.857, p = 0.003), multiple tumors (HR = 1.715, p < 0.001), and prior surgery (HR = 0.638, p = 0.013) were significantly associated with overall survival. Patients receiving surgery alone had better overall survival compared with patients receiving no treatment (p = 0.008) and patients receiving both surgery and radiotherapy (p = 0.002). The calibration plots demonstrated an excellent agreement between nomogram-predicted and actual survival.

Conclusion: In conclusion, age, race, tumor location, number of tumors, and prior surgery are prognostic factors for survival. Surgery was the most common modality and was suggested as an effective and optimal treatment. The proposed nomogram can predict the prognosis of patients with CNS hemangioblastomas and help clinicians in making decisions.

Keywords: SEER; hemangioblastoma; incidence; nomogram; prognosis; survival; treatment.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier curves for patients with CNS hemangioblastomas by different variates. (A) Age; (B) Gender; (C) Race; (D) Marital status; (E) Tumor size; (F) Tumor location; (G) Tumor number; (H) Prior surgery; (I) Extent of resection; (J) Prior radiotherapy.
FIGURE 2
FIGURE 2
Kaplan–Meier curves for patients with CNS hemangioblastomas by treatment modality.
FIGURE 3
FIGURE 3
Nomograms predicting 3- and 5-year survival of patients with CNS hemangioblastoma.
FIGURE 4
FIGURE 4
Calibration plots of the nomogram for OS prediction at 3-year (A) and 5-year (B).
See this image and copyright information in PMC

References

    1. Kanno H, Kobayashi N, Nakanowatari S. Pathological and clinical features and management of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Kidney Cancer VHL. (2014) 1:46–55. 10.15586/jkcvhl.2014.12 - DOI - PMC - PubMed
    1. Rachinger J, Buslei R, Prell J, Strauss C. Solid haemangioblastomas of the CNS: a review of 17 consecutive cases. Neurosurg Rev. (2009) 32:37–47. 10.1007/s10143-008-0166-0 - DOI - PubMed
    1. Bründl E, Schödel P, Ullrich OW, Brawanski A, Schebesch KM. Surgical resection of sporadic and hereditary hemangioblastoma: our 10-year experience and a literature review. Surg Neurol Int. (2014) 5:138. 10.4103/2152-7806.141469 - DOI - PMC - PubMed
    1. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. (2003) 361:2059–67. 10.1016/s0140-6736(03)13643-4 - DOI - PubMed
    1. Vortmeyer AO, Falke EA, Gläsker S, Li J, Oldfield EH. Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms. Acta Neuropathol. (2013) 125:333–50. 10.1007/s00401-013-1091-z - DOI - PubMed

LinkOut - more resources